



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7: C07J 1/00, A61K 31/565	A1	(11) International Publication Number: WO 00/23460 (43) International Publication Date: 27 April 2000 (27.04.00)
(21) International Application Number: PCT/EP99/07768 (22) International Filing Date: 11 October 1999 (11.10.99) (30) Priority Data: 98203460.5 16 October 1998 (16.10.98) EP (71) Applicant (for all designated States except US): AKZO NOBEL N.V. [NL/NL]; Velperweg 76, NL-6824 BM Arnhem (NL). (72) Inventors; and (75) Inventors/Applicants (for US only): KIRCHHOLTES, Peter, Huub, Gerard, Maria [NL/NL]; Gewandeweg 58, NL-5345 HN Oss (NL). SAS, Gerard, Arnoud, Jozef, Maria, Theresia [NL/NL]; Vlas en Graan 79, NL-5461 KL Veghel (NL). (74) Agent: HERMANS, Frans; P.O. Box 20, NL-5340 BH Oss (NL).		(81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: HIGH PURITY COMPOSITION COMPRISING (7 α ,17 α)- 17-HYDROXY- 7-METHYL- 19-NOR-17-PREGN-5(10)-EN-20-YN-3-ONE (57) Abstract The invention pertains to a process for the preparation of a high purity composition of (7 α ,17 α)- 17-hydroxy- 7-methyl- 19-nor-17-pregn- 5(10)-en-20-yn-3-one. The process provides for a composition with less than 0.5 % of (7 α ,17 α)- 17-hydroxy- 7-methyl- 19-nor-17-pregn- 4-en-20-yn- 3-one. This composition can be used as a source for the preparation of stable pharmaceutical dosage units.		

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY


Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

High purity composition comprising (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one

The invention relates to a high purity composition comprising (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one, a method for the preparation of this compound for use in the pharmaceutical composition as well as a pharmaceutical composition prepared by admixing a pharmaceutically suitable carrier and the high purity composition.

The compound (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one (Tibolone) having the structural formula 1:



Formula 1

is known, for example from US 3,340,279 and US Patent 4,701,450. The method described in these patents leads to a compound having combined oestrogenic, progestagenic and androgenic characteristics. This compound is used in medicaments having gonadomimetic, ovulation-inhibiting or immuno-modulating action.

Compositions comprising Tibolone and a pharmaceutically acceptable solid carrier have been described in EP 389 035, which disclosure is incorporated herein by reference. Tablets are available on the market under the name of Livial[®].

The known tablets can be stable stored very well for, typically, 2 years at ambient temperature. A sufficiently humid atmosphere (e.g. 50 - 70 % relative humidity) makes for a better storage stability than a relatively dry atmosphere (e.g. 45% relative humidity or below that).

A problem in the preparation of pharmaceutical dosage units is that during the preparation the relative amount of impurities may increase. In particular, the amount of one of the impurities which is already present in the bulk preparation i.e. (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-one (Org OM38) tends to increase
5 during the process of making pharmaceutical dosage units. It is furthermore known that the amounts of Org OM38 in compositions comprising Tibolone increase upon storage.

The end of shelf life specification with respect to the amount of Org OM38 formed during storage is 5%. A minimum acceptable shelf life period for these dosage units is 1 year. It is an object of the present invention to improve upon the storage stability i.e. to
10 enhance the shelf-life of the dosage units.

The customary amount of Tibolone in the known dosage unit is 2.5 mg in tablets or capsules of 100 mg, i.e. 2.5%. For the sake of providing therapies better tailored to the individual woman's needs, it is desired to provide dosage units having a lower amount.

15 However, adaptation of a known formulation by simply including a lower amount of Tibolone further decreases the stability of the dosage unit substantially. E.g., if a 2.5 mg Tibolone dosage unit has a shelf-life of, e.g., 2-3 years at room temperature, the same unit upon lowering the amount of Tibolone to e.g. 0.3 mg can only be kept at 4°C for a period of 6-12 months. Such a lower stability is unacceptable in daily practice. It is
20 a further object of the invention to provide dosage forms having a lower content of Tibolone (which are more prone to stability problems than regular dosage forms) and that can be suitably kept for a prolonged period of time.

One of the possibilities to keep the amount of Org OM-38 below a desired level
25 also after a prolonged storage time is to limit the amount initially present in the bulk preparation. Thus, there is a need to synthesize high purity Tibolone batches with a low contamination content of Org OM-38. It is an object of the present invention to provide for such high purity batches of Tibolone.

During the last step of the synthesis of Tibolone a solution of (7 α ,17 α)-3,3-dimethoxy-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one in a mixture of
30 pyridine and ethanol is mixed with a solution of oxalic acid in water and the mixture is stirred for 3 hours at approximately 30 °C. The solution is then poured out in a mixture of pyridine and water and the resulting suspension is filtered. The crystals are washed with a mixture of water and pyridine and subsequently, the crystals are dried under

vacuum at 40 °C to give (7 α ,17 α)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one (see also van Vliet et al (1986), Recl.Trav.Chim.Pays-Bas 105, 111-115).

As this compound has a lower stability than the corresponding (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-pregn-4-en-20-yn-3-one there is always formed a small
5 percentage of the latter compound via acid catalyzed isomerisation. Furthermore, this isomerisation takes place at higher temperature and upon long term storage of the crystals

Unexpectedly, it now has been found that the rate of formation of Org OM38 during
10 drying and storage in a specific batch can be decreased if crystals of Tibolone are washed with water and are allowed to age for at least 24 hours in the presence of water. Thus, the Tibolone is left for at least 24 hours under wet conditions. Preferentially the crystals are left under these conditions for a period of at least 3 days. There is no limit to a maximum period but a period of 3-6 days is best suited. The aging temperature
15 preferentially is room temperature.

Thus according to the procedure of the present invention highly pure Tibolone with a low Org OM38 impurity is obtained by including a delay of several days before drying. The procedure reliably results in batches of Tibolone having a low Org OM38 content. A further advantage is that these batches have an excellent stability. Furthermore, these
20 batches do not form additional amounts of the latter compound upon heating or long term storage.

The crystal formation procedure of the present invention can perfectly well be combined with the last step of the Tibolone synthesis wherein (7 α ,17 α)-3,3-dimethoxy-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one in a mixture of pyridine and
25 ethanol is mixed with a solution of oxalic acid in water. In general, this reaction proceeds under mild acidic conditions in the presence of an organic solvent and water within a pH range of 5-3, preferentially 3.5-4.5. The acid preferentially is a weak organic acid having a pKa value in the range 1-5 such as citric acid, malonic acid, oxalic acid, dichloroacetic acid and acetic acid, optionally buffered with a base such as pyridine. As
30 organic solvent e.g. ethanol, methanol, acetone, 2-propanol or tetrahydrofuran can be used. The solution is then poured out in water, which is made slightly alkaline by addition e.g. of a low amount of pyridine. After filtering the suspension the crystals are washed with a mixture of water made slightly alkaline by e.g. pyridine. Before drying the crystals are left wet for at least 24 hours.

Inclusion of the crystal aging step according to the invention results in bulk Tibolone batches with a low Org OM38 content. Routinely, batches are obtained with an Org OM38 content of less than 0.5%. Often even batches with less than 0.25% or even 0.1% of Org OM38 are obtained. Thus high purity compositions with Tibolone having
5 less than 0.5% of Org OM38, preferably 0.25%, more preferably 0.10% of Org OM38 form part of the present invention. The amount of Org OM38 is calculated as the percentage (w/w) of the total amount of the bulk substance including some minor impurities. The amount of Tibolone usually is more than 98%.

The batches of these high purity Tibolone compositions with their low initial Org
10 OM38 content are perfectly well suited to be used as a source for the preparations of pharmaceutical formulations. This guarantees a formulation with a low initial Org OM38 content and improves therefore its storage properties. Pharmaceutical preparations prepared with high purity Tibolone usually result in preparations with less than 1% of Org OM38, often even less than 0.7% of Org OM38 and these preparations
15 are less prone to increase in Org OM38 content during storage.

As indicated before the amount of Org OM38 in a dosage form also depends upon the concentration of the active substance, the amount of impurity being higher as the amount of Tibolone in the dosage unit decreases. Therefore, using high purity Tibolone as the active substance, dosage units can now be prepared with a lower amount of
20 Tibolone and still having an acceptable shelf life. Thus, the invention also relates to pharmaceutical dosage units, which can be prepared by admixture of a pharmaceutically suitable solid carrier and the high purity composition of the present invention.

A typical known formulation for Tibolone is a 100 mg dosage unit having 2.5 mg of Tibolone contained therein, a relatively small amount (e.g. approximately 1 % by
25 weight) of pharmaceutically acceptable auxiliaries, and a carrier making up the body of the tablet. The carrier typically is composed of 10 % by weight of starch, e.g. potato starch, and 90 % by weight of lactose.

Due to the excellent stability properties of dosage units with a lower amount of active substance than the present commercially available tablets of 2.5 mg active
30 substance, the present invention now makes it also possible to provide for stable dosage units comprising Tibolone in an amount of less than 2.50 mg, preferably 1.25 mg or less, more preferably 0.625 mg or less. At a shelf life of 1.5 years, preferably 2 years these dosage units still comprise less than 5% of OM38 (relative to the amount of Tibolone).

It is another aspect of the present invention to provide dosage units comprising
35 Tibolone in amounts of less than 2.50 mg, preferably 1.25 mg or less, more preferably

0.625 mg or less and comprising at a shelf life of 6 months less than 3 %, preferably 2 % of OM38. The shelf life preferably is extended up to 1 year, preferably 1.5 year, more preferably 2 years.

As used herein shelf life means storage during a specified period under temperature
5 conditions varying from 2-25 °C. Dosage units can be packed e.g. in push-through packs (PTP, blister) and are preferably stored in dark (e.g. enclosed in carton). Alternatively they might also be stored in bottles e.g. high-density polyethylene bottles.

The pharmaceutical dosage units of the present invention will generally take the form of tablets or capsules, but other solid or dry pharmaceutical preparations are
10 included.

Methods for making such dosage units are well known. For example in the standard English language text Gennaro et al., Remington's Pharmaceutical Sciences, (18th ed., Mack Publishing Company, 1990, see especially Part 8: Pharmaceutical Preparations and Their Manufacture), methods of making tablets, capsules and pills and their
15 respective components are described.

Tablets and capsules are prepared of granulates using dry or wet granulation techniques as disclosed in The Theory and Practice of Industrial Pharmacy (Third edition) L. Lachman, H.A. Lieberman and J. L. Kanig (1986) p 1 -99 and 293 - 345.

The aim of granulation is to improve the flowability and compressibility of the
20 powder mixture. Wet granulation forms the granules by binding the powders (a mixture of a diluent and disintegrant) together with an adhesive. The wet granulation technique employs a solution, suspension or slurry containing a binder, which is usually added to the powder mixture; however the binder may be incorporated dry to the powder mix and the liquid may be added by itself. The wet granulation process is performed in
25 mixers/kneaders or fluid bed systems.

Usually an amount of water is incorporated in the basic granulate ranging from 5.5 - 7 %. Preferably the amount of water incorporated is at least 6%.

After granulation the mass is dried to the desired water content using fluid bed dryers, tray dryers, vacuum dryers or other suitable dryers.

30 To attain a good distribution of the active (Tibolone) over the total mass, the active is premixed with a part of the granulate, sieved using an oscillating sieve, a high speed sieve or other suitable sieving equipment. Next this mixture is mixed with the remaining part of the granulate and a lubricant. This mixture is compressed to tablets, or filled into capsules.

The following examples are illustrative for the invention and should in no way be interpreted as limiting the scope of the invention.

5

Examples

Example 1

A solution of (7 α ,17 α)-3,3-dimethoxy-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one (15 kg) in a mixture of pyridine (630 ml) and ethanol (315 litres) was mixed with a solution of oxalic acid (750 gr) in water (90 litres) and the mixture was stirred for 2 hours at approximately 30 °C. The solution was poured out in a mixture of pyridine (1350 ml) and water (300 litres) and the resulting suspension was filtered. The crystals were washed with a mixture of water and pyridine and dried under vacuum at 40 °C to give (7 α ,17 α)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one containing 0.6% of the corresponding (7 α ,17 α)-17-hydroxy-7-methyl-19-norpregn-4-en-20-yn-3-one as indicated by HPLC analysis; a stress test at 45 °C (duration 1 month) indicated a 0.4% increase of the latter compound.

20 Example 2

A solution of (7 α ,17 α)-3,3-dimethoxy-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one (15 kg) in a mixture of pyridine (630 ml) and ethanol (315 litres) was mixed with a solution of oxalic acid (375 gr) in water (90 litres) and the mixture was stirred for 3 hours at approximately 30 °C. The solution was poured out in a mixture of pyridine (1350 ml) and water (300 litres) and the resulting suspension is filtered. The crystals are washed with a mixture of water and pyridine and allowed to age for 3-6 days at room temperature. Subsequently, the crystals were dried under vacuum at 40 °C to give (7 α ,17 α)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one containing \leq 0.1% of the corresponding (7 α ,17 α)-17-hydroxy-7-methyl-19-norpregn-4-en-20-yn-3-one as indicated by HPLC analysis; a stress test at 45 °C (duration 1 week) indicated a < 0.1% increase of the latter compound.

30

Example 3

The preparation as described in example 2 was repeated. (7 α ,17 α)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one was obtained which contained 0.2 % of the corresponding (7 α ,17 α)-17-hydroxy-7-methyl-19-norpregn-4-en-20-yn-3-one as indicated by HPLC analysis; a stress test at 45 °C (duration 1 week) indicated a 0.1% increase of the latter compound.

Example 4

A basic granulate was prepared by granulation of a mixture of lactose (diluent), potato starch (disintegrant) and potato starch mucilage (binder) in a fluid bed granulator. The water content of the granulate varied within 5.5% - 6.5%. After granulation, the basic granulate was passed through a conical high speed sieve. Part of the granulate (10 % w/w) was mixed with Tibolone and ascorbyl palmitate using a tumble blender and then passed through a conical high speed sieve.

The Tibolone premix and the remainder of the basic granulate were mixed in a ribbon blender. Magnesium stearate was added and mixed. The final granulate was compressed into round tablets.

The stability of the active compound (Tibolone) in tablets was determined.

Table 1: Content of decomposition product (Org OM38) in percentage of the declared amount of Tibolone per tablet, in tablets containing a various amount of Tibolone, after storage at 25°C and 60% relative humidity.

Storage time (months)	Concentration of Tibolone per tablet			
	0.46	0.96	1.92	2.5
	Amount of Org OM38 formed during storage (in percentage of the declared amount of tibolone)			
0	1.2	0.8	0.5	0.4
6	6.5	3.5	1.8	1.6
12	9.5	5.1	2.7	2.2
18	12.2	6.1	3.3	2.7

Example 5

Tablets of 1.25 mg of Tibolone have been prepared as described in example 4. The tablets were stored at 25°C and 60% relative humidity and the decomposition product (Org OM38) was measured.

5

Table 2: Content of decomposition product (Org OM38) in percentage of the declared amount of Tibolone per tablet. Stability of three development tablet batches (1.25 mg of Tibolone per 65 mg) was assessed (storage at 25°C and 60% relative humidity).

Storage time (months)	Batch no		
	049514001	049515001	049516001
	Amount of Org OM38 formed during storage (in percentage of the declared amount of Tibolone)		
0	0.7	1.0	1.3
6	2.3	2.6	2.9
12	3.5	3.7	3.8
18	4.3	4.2	4.3
24	5.1	4.9	4.9

10 It can be concluded that the shelf life of tablets containing 1.25 mg of Tibolone per
tablet of 65 mg is borderline .

Example 6

15 Tibolone as prepared as in example 2 was used as the active compound to prepare
tablets as described in example 4. The amount of Org OM38 formed in several batches
during storage was determined.

Table 3: The stability of six tablet batches (1.25 mg of Tibolone per 65 mg) was assessed (storage at 25°C and 60% relative humidity). The amount of water incorporated in the basic granulate was varied from 6.0% to 6.5%.

Storage time (months)	Batch no					
	TD96.1128	TD96.1132	TD96.1133	162454001	162455001	162456001
	Amount of Org OM38 formed during storage (in percentage of the declared amount of Tibolone)					
0	0.7	0.5	0.5	0.9	0.8	0.9
6	1.3	1.1	1.1	1.8	1.7	1.8
12	1.8	1.5	1.6			
18	2.0	1.5	1.7			
Water content of the basic granulate	6.5	6.5	6.5	6.3	6.1	6.1

Claims

1. A high purity composition comprising (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one, characterized in that the said composition comprises
5 (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-one in an amount less than 0.5%.
2. The composition according to claim 1 characterized in that the amount of (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-one is 0.25% or less.
3. The composition according to claim 1 characterized in that the amount of (7 α ,17 α)-
10 17-hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-one is 0.1% or less.
4. A process for preparing the high purity compositions of claims 1-3 characterized in that crystals of (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one are allowed to age in the presence of water for at least 24 hours.
5. The process according to claim 4 wherein the aging lasts 3-6 days.
- 15 6. The process according to claims 4 or 5 characterized in that the crystals are formed in the last step of the Tibolone synthesis comprising the steps of
 - a. reacting (7 α ,17 α)-3,3-dimethoxy-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one in an organic solvent with a weak acidic aqueous solution
 - b. pouring out the solution in water which is made slightly alkaline
 - 20 c. washing the crystals with water which is made slightly alkaline.
7. A pharmaceutical dosage unit obtainable by admixture of a pharmaceutically suitable solid carrier and the composition according to any one of the claims 1-3.
8. A pharmaceutical dosage unit obtainable by admixture of a pharmaceutically suitable solid carrier and the composition obtainable by the process of claims 4-6.
- 25 9. A dosage unit comprising a pharmaceutically suitable solid carrier and (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one in an amount of less than 2.50 mg and having a shelf life specification comprising less than 5% of (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-one.
10. The dosage unit according to claim 9 characterized in that (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one is present in an amount of 1.25 mg
30 or less.

11. The dosage unit according to claim 9 characterized in that (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one is present in an amount of 0.625 mg or less.
12. The dosage unit according to claims 9-11 wherein the shelf life is 1.5 , more
5 preferably 2 years.
13. The dosage unit according to claim 9-11 wherein at a shelf life period of 6 months the amount of (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-one is 3 % or less, more preferably 2% or less.
14. The dosage unit according to claim 13 wherein the shelf life period is 1, preferably
10 1 ½ year, more preferably 2 years.

C.(Continuation) DOCUMENT CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 707 848 A (AKZO NOBEL NV) 24 April 1996 (1996-04-24) example 3 ---	9-14
X	EP 0 613 687 A (AKZO NOBEL NV) 7 September 1994 (1994-09-07) example 2 ---	9
X	EP 0 159 739 A (AKZO NV) 30 October 1985 (1985-10-30) example 1 ---	9
A	VAN VLIET N P ET AL: "An alternative synthesis of 17.beta.-hydroxy-7.alpha.-methyl-19-nor -17.alpha.-pregn-5(10)-en-20-yn-3-one (Org OD 14)" RECUEIL DES TRAVAUX CHIMIQUES DES PAYS-BAS., vol. 105, no. 4, April 1986 (1986-04), pages 111-115, XP002099865 AMSTERDAM NL page 113, column 1, last paragraph page 115, column 1, paragraph 4 ---	1-14
A	DECLERCQ J P ET AL: "Conformational analysis of 3-oxo 5(10)-unsaturated steroids. Single-crystal x-ray structure analysis of 17-hydroxy-7.alpha.-methyl -19-nor-17.alpha.-pregn-5(10)-en-20-yn-3-o ne (Org OD 14)" RECUEIL DES TRAVAUX CHIMIQUES DES PAYS-BAS., vol. 103, no. 5, May 1984 (1984-05), pages 145-147, XP002099866 AMSTERDAM NL page 146, column 1; table I ---	1-14
A	WIELAND P ET AL: "Steroids. CCXI. Synthesis of 7.alpha.-methyl-3-oxo-19-norandrosta -4,9,11-trienes" HELVETICA CHIMICA ACTA, vol. 50, no. 6, 21 September 1967 (1967-09-21), pages 1453-1461, XP002099867 BASEL CH page 1459, paragraph 1 ---	1-14
A	US 3 340 279 A (H. P. DE JONGH ET AL) 5 September 1967 (1967-09-05) examples I, II --- -/--	1-14

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/07768

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	FR 1 583 441 A (THE UPJOHN COMPANY) 31 October 1969 (1969-10-31) example 16 ---	1-14
A	US 3 475 465 A (WINTER MAX SOLOMON DE ET AL) 28 October 1969 (1969-10-28) example II ---	1-14
A	US 3 432 528 A (ANNER GEORG ET AL) 11 March 1969 (1969-03-11) example 3 ---	1-14
A	US 3 576 828 A (ANNER GEORG ET AL) 27 April 1971 (1971-04-27) example 9 -----	1-14

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 99/07768

Patent document cited in search		Publication date	Patent family member(s)		Publication date
EP 0389035	A	26-09-1990	AT	98490 T	15-01-1994
			AU	625083 B	02-07-1992
			AU	5139490 A	20-09-1990
			CA	2011452 A	18-09-1990
			DE	69005165 D	27-01-1994
			DE	69005165 T	05-05-1994
			DK	389035 T	14-02-1994
			ES	2062292 T	16-12-1994
			FI	94865 B	31-07-1995
			HK	1002019 A	24-07-1998
			IE	63051 B	22-03-1995
			JP	3047195 A	28-02-1991
			MX	9203787 A	01-07-1992
			NZ	232946 A	27-08-1991
			PT	93488 A,B	07-11-1990
			US	5037817 A	06-08-1991
WO 9847517	A	29-10-1998	AU	8014698 A	13-11-1998
			JP	10316573 A	02-12-1998
			NO	995127 A	21-10-1999
			ZA	9803169 A	20-10-1998
WO 9839012	A	11-09-1998	AU	6728498 A	22-09-1998
			ZA	9801731 A	07-09-1998
WO 8909058	A	05-10-1989	AU	3435989 A	16-10-1989
			DK	224690 A	18-09-1990
			EP	0406279 A	09-01-1991
			JP	3503414 T	01-08-1991
EP 0707848	A	24-04-1996	AU	688581 B	12-03-1998
			AU	3426795 A	02-05-1996
			BR	9504400 A	27-05-1997
			CA	2159419 A	18-04-1996
			CN	1130064 A	04-09-1996
			FI	954905 A	18-04-1996
			HU	75247 A	28-05-1997
			IL	115445 A	17-08-1999
			JP	8268914 A	15-10-1996
			TR	960302 A	21-06-1996
EP 0613687	A	07-09-1994	AT	180669 T	15-06-1999
			AU	671706 B	05-09-1996
			AU	5754294 A	08-09-1994
			CA	2116829 A	06-09-1994
			DE	69418744 D	08-07-1999
			DE	69418744 T	11-11-1999
			ES	2134313 T	01-10-1999
			JP	7002673 A	06-01-1995
			NO	940777 A	06-09-1994
			NZ	260017 A	24-06-1997
			US	5512556 A	30-04-1996
			ZA	9401464 A	27-09-1994
EP 0159739	A	30-10-1985	AT	42895 T	15-05-1989
			JP	1829698 C	15-03-1994
			JP	60209599 A	22-10-1985
			MX	9203811 A	01-07-1992

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 99/07768

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0159739	A		US 4701450 A	20-10-1987
US 3340279	A	05-09-1967	NL 6406797 A	17-12-1965
			BE 665514 A	
			CH 517725 A	15-01-1972
			DE 1543273 A	07-08-1969
			DK 114553 B	14-07-1969
			FR 1594513 A	08-06-1970
			GB 1104462 A	
			SE 336788 B	19-07-1971
FR 1583441	A	31-10-1969	BE 712229 A	16-09-1968
			CH 516545 A	15-12-1971
			DE 1668818 A	30-09-1971
			GB 1206872 A	30-09-1970
			GB 1206873 A	30-09-1970
			GB 1206874 A	30-09-1970
			NL 6803328 A	16-09-1968
			US 3515719 A	02-06-1970
US 3475465	A	28-10-1969	NL 6608779 A	27-12-1967
			BE 700390 A	27-12-1967
			CH 537913 A	31-07-1973
			DE 1618747 A	25-02-1971
			DK 115989 B	01-12-1969
			FR 1527563 A	06-11-1968
			GB 1177845 A	14-01-1970
US 3432528	A	11-03-1969	BE 684851 A	30-01-1967
			BE 684852 A	30-01-1967
			CH 488682 A	15-04-1970
			CH 509996 A	15-07-1971
			CH 519488 A	29-02-1972
			CH 525873 A	31-07-1972
			DE 1568308 A	05-02-1970
			DE 1568306 A	12-03-1970
			DE 1568307 A	05-02-1970
			FR 5260 M	24-07-1967
			FR 6350 M	07-10-1968
			FR 1491586 A	30-11-1967
			FR 1491587 A	30-11-1967
			FR 1491588 A	30-11-1967
			GB 1158331 A	16-07-1969
			GB 1158332 A	16-07-1969
			NL 6610741 A,B	31-01-1967
			NL 6610742 A,B	31-01-1967
			NL 6610743 A,B	31-01-1967
			NL 7607401 A	29-10-1976
			US 3576828 A	27-04-1971
			ES 329609 A	01-03-1968
			CS 153439 B	25-02-1974
US 3576828	A	27-04-1971	BE 684851 A	30-01-1967
			BE 684852 A	30-01-1967
			CH 488682 A	15-04-1970
			CH 509996 A	15-07-1971
			CH 519488 A	29-02-1972
			CH 525873 A	31-07-1972

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 3576828 A		DE 1568308 A	05-02-1970
		DE 1568306 A	12-03-1970
		DE 1568307 A	05-02-1970
		FR 5260 M	24-07-1967
		FR 6350 M	07-10-1968
		FR 1491586 A	30-11-1967
		FR 1491587 A	30-11-1967
		FR 1491588 A	30-11-1967
		GB 1158331 A	16-07-1969
		GB 1158332 A	16-07-1969
		NL 6610741 A,B	31-01-1967
		NL 6610742 A,B	31-01-1967
		NL 6610743 A,B	31-01-1967
		NL 7607401 A	29-10-1976
		US 3432528 A	11-03-1969
		ES 329609 A	01-03-1968
		CS 153439 B	25-02-1974

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☒ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.